sars cov 2  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Name:
    SARS CoV 2 2019 nCoV Spike S2 mFc Recombinant Protein
    Description:
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike Protein S2 ECD YP 009724390 1 Ser686 Pro1213 was expressed with the Fc region of mouse IgG1 at the C terminus
    Catalog Number:
    40590-V05B
    Price:
    None
    Category:
    recombinant protein
    Product Aliases:
    coronavirus spike Protein 2019-nCoV, cov spike Protein 2019-nCoV, ncov RBD Protein 2019-nCoV, ncov s1 Protein 2019-nCoV, ncov s2 Protein 2019-nCoV, ncov spike Protein 2019-nCoV, NCP-CoV RBD Protein 2019-nCoV, NCP-CoV s1 Protein 2019-nCoV, NCP-CoV s2 Protein 2019-nCoV, NCP-CoV Spike Protein 2019-nCoV, novel coronavirus RBD Protein 2019-nCoV, novel coronavirus s1 Protein 2019-nCoV, novel coronavirus s2 Protein 2019-nCoV, novel coronavirus spike Protein 2019-nCoV, RBD Protein 2019-nCoV, S1 Protein 2019-nCoV, S2 Protein 2019-nCoV, Spike RBD Protein 2019-nCoV
    Host:
    Baculovirus-Insect Cells
    Buy from Supplier


    Structured Review

    Sino Biological sars cov 2
    Pilot Scale Production of RBD-SC-Dimers of MERS-CoV and <t>SARS-CoV-2</t> (A) RBD-sc-dimers were produced in industry-standard CHO cell system in GMP grade manufacturing. The immunogen yields and purities for vaccine stock solution are shown. (B) Non-reduced SDS-PAGE migration profile of increasing amounts of GMP grade RBD-sc-dimers are shown.
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike Protein S2 ECD YP 009724390 1 Ser686 Pro1213 was expressed with the Fc region of mouse IgG1 at the C terminus
    https://www.bioz.com/result/sars cov 2/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 - by Bioz Stars, 2021-04
    95/100 stars

    Images

    1) Product Images from "A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS"

    Article Title: A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

    Journal: Cell

    doi: 10.1016/j.cell.2020.06.035

    Pilot Scale Production of RBD-SC-Dimers of MERS-CoV and SARS-CoV-2 (A) RBD-sc-dimers were produced in industry-standard CHO cell system in GMP grade manufacturing. The immunogen yields and purities for vaccine stock solution are shown. (B) Non-reduced SDS-PAGE migration profile of increasing amounts of GMP grade RBD-sc-dimers are shown.
    Figure Legend Snippet: Pilot Scale Production of RBD-SC-Dimers of MERS-CoV and SARS-CoV-2 (A) RBD-sc-dimers were produced in industry-standard CHO cell system in GMP grade manufacturing. The immunogen yields and purities for vaccine stock solution are shown. (B) Non-reduced SDS-PAGE migration profile of increasing amounts of GMP grade RBD-sc-dimers are shown.

    Techniques Used: Produced, SDS Page, Migration

    Design and Assessment of RBD-SC-Dimer as a Vaccine against SARS-CoV-2 (A) A schematic diagram of SARS-CoV-2 RBD-sc-dimer. Two SARS-CoV-2 RBD (R319-K537) were dimerized as tandem repeat (SP, signal peptide). Analytical gel filtration of SARS-CoV-2 RBD-sc-dimer protein was performed with HiLoad 16/600 Superdex 200 pg. The 280-nm absorbance curve is shown. Non-reduced and reduced SDS-PAGE migration profiles of the pooled samples are shown. (B) Ultracentrifugation sedimentation profiles of SARS-CoV-2 RBD-sc-dimer. (C) Representative BIAcore diagrams of SARS-CoV-2 RBD-sc-dimer and monomer bound to hACE2 protein. The K D value was calculated by the software BIAevaluation Version 4.1 (GE Healthcare). The values shown are mean ± SD of two independent experiments. (D and E) Groups of BALB/c mice were immunized with a 10-μg dose of SARS-CoV-2 RBD-sc-dimer and conventional RBD-monomer, respectively, with AddaVax as adjuvant. PBS formulated with adjuvant was given as control. A three-dose vaccination regimen was performed. Serum samples were collected after each immunization (19 days after 1 st immunization, 14 days after 2 nd immunization, and 14 days after 3 rd immunization) to evaluate the humoral response dynamics. ELISA assay shows the SARS-CoV-2 RBD specific IgG titers in (D) and SARS-CoV-2 pseudovirus neutralization assay shows the NT 90 in (E). The values shown in (D) and (E) are the mean ± SEM. The horizontal dashed line indicates the limit of detection. P-values were analyzed with one-way ANOVA (ns, p > 0.05; ∗ p
    Figure Legend Snippet: Design and Assessment of RBD-SC-Dimer as a Vaccine against SARS-CoV-2 (A) A schematic diagram of SARS-CoV-2 RBD-sc-dimer. Two SARS-CoV-2 RBD (R319-K537) were dimerized as tandem repeat (SP, signal peptide). Analytical gel filtration of SARS-CoV-2 RBD-sc-dimer protein was performed with HiLoad 16/600 Superdex 200 pg. The 280-nm absorbance curve is shown. Non-reduced and reduced SDS-PAGE migration profiles of the pooled samples are shown. (B) Ultracentrifugation sedimentation profiles of SARS-CoV-2 RBD-sc-dimer. (C) Representative BIAcore diagrams of SARS-CoV-2 RBD-sc-dimer and monomer bound to hACE2 protein. The K D value was calculated by the software BIAevaluation Version 4.1 (GE Healthcare). The values shown are mean ± SD of two independent experiments. (D and E) Groups of BALB/c mice were immunized with a 10-μg dose of SARS-CoV-2 RBD-sc-dimer and conventional RBD-monomer, respectively, with AddaVax as adjuvant. PBS formulated with adjuvant was given as control. A three-dose vaccination regimen was performed. Serum samples were collected after each immunization (19 days after 1 st immunization, 14 days after 2 nd immunization, and 14 days after 3 rd immunization) to evaluate the humoral response dynamics. ELISA assay shows the SARS-CoV-2 RBD specific IgG titers in (D) and SARS-CoV-2 pseudovirus neutralization assay shows the NT 90 in (E). The values shown in (D) and (E) are the mean ± SEM. The horizontal dashed line indicates the limit of detection. P-values were analyzed with one-way ANOVA (ns, p > 0.05; ∗ p

    Techniques Used: Filtration, SDS Page, Migration, Sedimentation, Software, Mouse Assay, Enzyme-linked Immunosorbent Assay, Neutralization

    Characterization of the Cellular Immune Response for COVID-19 Vaccine, Related to Figure 3 Fourty-five after the last vaccination, the splenocytes were isolated from mice vaccinated with SARS-CoV-2 RBD-sc-dimer (plus AddaVax TM adjuvant) and PBS (plus AddaVax TM adjuvant), respectively. (A) ELISPOT assay was performed to evaluate the ability of splenocytes to secrete IFN-γ following stimulation with different concentrations of peptide pool of SARS-CoV-2 RBD (2 μg/mL, 10 μg/mL and 50 μg/mL). Spot-forming cells (SFCs) per million cells are shown. (B) An ICS assay was conducted to quantify the proportion of CD8+ and CD4+ T cells producing key cytokines (IFN-γ, IL-2, TNF-α and IL-4) following stimulation with 10 μg/mL peptide pool (SARS-CoV-2 RBD). Shown are the frequencies of respective cytokine-producing cells. The values are the mean ± SEM. P-values were analyzed with unpaired t test (ns, p > 0.05).
    Figure Legend Snippet: Characterization of the Cellular Immune Response for COVID-19 Vaccine, Related to Figure 3 Fourty-five after the last vaccination, the splenocytes were isolated from mice vaccinated with SARS-CoV-2 RBD-sc-dimer (plus AddaVax TM adjuvant) and PBS (plus AddaVax TM adjuvant), respectively. (A) ELISPOT assay was performed to evaluate the ability of splenocytes to secrete IFN-γ following stimulation with different concentrations of peptide pool of SARS-CoV-2 RBD (2 μg/mL, 10 μg/mL and 50 μg/mL). Spot-forming cells (SFCs) per million cells are shown. (B) An ICS assay was conducted to quantify the proportion of CD8+ and CD4+ T cells producing key cytokines (IFN-γ, IL-2, TNF-α and IL-4) following stimulation with 10 μg/mL peptide pool (SARS-CoV-2 RBD). Shown are the frequencies of respective cytokine-producing cells. The values are the mean ± SEM. P-values were analyzed with unpaired t test (ns, p > 0.05).

    Techniques Used: Isolation, Mouse Assay, Enzyme-linked Immunospot

    Related Articles

    Isolation:

    Article Title: Tackling the COVID-19 “cytokine storm” with microRNA mimics directly targeting the 3’UTR of pro-inflammatory mRNAs
    Article Snippet: .. The experimental plan should verify (a) response to different concentrations of SARS-CoV-2 Spike protein for different length of time; (b) co-treatment with different concentrations of pre-miRNA targeting pro-inflammatory mRNA that have been found over-expressed on COVID-19; (c) isolation of RNA and quantitation of pro-inflammatory mRNA by RT-qPCR; (d) analysis of the secretome profile. .. Recombinant SARS spike glycoprotein is commercially available.

    Quantitation Assay:

    Article Title: Tackling the COVID-19 “cytokine storm” with microRNA mimics directly targeting the 3’UTR of pro-inflammatory mRNAs
    Article Snippet: .. The experimental plan should verify (a) response to different concentrations of SARS-CoV-2 Spike protein for different length of time; (b) co-treatment with different concentrations of pre-miRNA targeting pro-inflammatory mRNA that have been found over-expressed on COVID-19; (c) isolation of RNA and quantitation of pro-inflammatory mRNA by RT-qPCR; (d) analysis of the secretome profile. .. Recombinant SARS spike glycoprotein is commercially available.

    Quantitative RT-PCR:

    Article Title: Tackling the COVID-19 “cytokine storm” with microRNA mimics directly targeting the 3’UTR of pro-inflammatory mRNAs
    Article Snippet: .. The experimental plan should verify (a) response to different concentrations of SARS-CoV-2 Spike protein for different length of time; (b) co-treatment with different concentrations of pre-miRNA targeting pro-inflammatory mRNA that have been found over-expressed on COVID-19; (c) isolation of RNA and quantitation of pro-inflammatory mRNA by RT-qPCR; (d) analysis of the secretome profile. .. Recombinant SARS spike glycoprotein is commercially available.

    other:

    Article Title: A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
    Article Snippet: RBD-sc-dimer of SARS-CoV-2 was two RBD (S protein residues 319–537) connected as tandem repeat.

    Article Title: Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2
    Article Snippet: SARS-CoV-2 spike protein was probed with the mouse anti-spike antibody.

    Article Title: CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation
    Article Snippet: Introduction The outbreak of 2019-novel coronavirus (SARS-CoV-2), the etiological agent of Coronavirus Disease 2019 (COVID-19), began in Wuhan, China in late 2019 and quickly spread across the globe causing epidemics on every continent except Antarctica in under four months.

    Binding Assay:

    Article Title: Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2
    Article Snippet: Flow cytometryTransfected cells were sorted for HDR+ by staining for Strep-Tactin-APC 1:100 (IBA lifesciences, Cat: 6-5010-001) and anti-hIgG AF488 1:100 (Jackson ImmunoResearch, Cat: 109-545-003). .. Enriched cells were then selected for antigen binding by incubating with SARS-CoV-2 S1-mFc 1:75 (Sinobiological, Cat: 40591-V05H1), S2-mFc 1:75 (Sinobiological, Cat: 40590-V05B) on ice for 20 min, followed by a single wash and a secondary staining with anti-mFc IgG1: PE and/or APC [clone RMG1-1] at 1:100 (Biolegend, Cat: 406608/406610). .. After enrichment for S1, cells were also tested for binding to SARS-CoV-2 RBD-mFc 1:375 (Sinobiological, Cat: 40592-V05H), and the same secondary staining.

    Staining:

    Article Title: Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2
    Article Snippet: Flow cytometryTransfected cells were sorted for HDR+ by staining for Strep-Tactin-APC 1:100 (IBA lifesciences, Cat: 6-5010-001) and anti-hIgG AF488 1:100 (Jackson ImmunoResearch, Cat: 109-545-003). .. Enriched cells were then selected for antigen binding by incubating with SARS-CoV-2 S1-mFc 1:75 (Sinobiological, Cat: 40591-V05H1), S2-mFc 1:75 (Sinobiological, Cat: 40590-V05B) on ice for 20 min, followed by a single wash and a secondary staining with anti-mFc IgG1: PE and/or APC [clone RMG1-1] at 1:100 (Biolegend, Cat: 406608/406610). .. After enrichment for S1, cells were also tested for binding to SARS-CoV-2 RBD-mFc 1:375 (Sinobiological, Cat: 40592-V05H), and the same secondary staining.

    Clone Assay:

    Article Title: Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
    Article Snippet: .. Three to four rounds of panning were performed to enrich for scFv phage clones that specifically bound the SARS-CoV-2 spike protein. .. Antibody characterization by ELISAHigh binding plates (Corning) were coated with 2 mg/mL coronavirus spike proteins (the spike proteins and their variants are purchased from Sino biological) at least 2 hours at room temperature (RT).

    Expressing:

    Article Title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Article Snippet: Supernatants were also collected on day 5 for antibody purification using rProtein A Sepharose (GE, 17-1279-01) affinity chromatography. .. Production of pseudovirusesRecombinant Indiana vesicular stomatitis virus (rVSV) expressing the SARS-CoV-2 spike was generated as previously described31,32. .. HEK293T cells were grown to 80% confluency before transfection with pCMV3-SARS-CoV-2-spike (Sino Biological) using FuGENE 6 (Promega).

    Generated:

    Article Title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Article Snippet: Supernatants were also collected on day 5 for antibody purification using rProtein A Sepharose (GE, 17-1279-01) affinity chromatography. .. Production of pseudovirusesRecombinant Indiana vesicular stomatitis virus (rVSV) expressing the SARS-CoV-2 spike was generated as previously described31,32. .. HEK293T cells were grown to 80% confluency before transfection with pCMV3-SARS-CoV-2-spike (Sino Biological) using FuGENE 6 (Promega).

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Sino Biological sars cov 2
    Pilot Scale Production of RBD-SC-Dimers of MERS-CoV and <t>SARS-CoV-2</t> (A) RBD-sc-dimers were produced in industry-standard CHO cell system in GMP grade manufacturing. The immunogen yields and purities for vaccine stock solution are shown. (B) Non-reduced SDS-PAGE migration profile of increasing amounts of GMP grade RBD-sc-dimers are shown.
    Sars Cov 2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 - by Bioz Stars, 2021-04
    95/100 stars
      Buy from Supplier

    Image Search Results


    Pilot Scale Production of RBD-SC-Dimers of MERS-CoV and SARS-CoV-2 (A) RBD-sc-dimers were produced in industry-standard CHO cell system in GMP grade manufacturing. The immunogen yields and purities for vaccine stock solution are shown. (B) Non-reduced SDS-PAGE migration profile of increasing amounts of GMP grade RBD-sc-dimers are shown.

    Journal: Cell

    Article Title: A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

    doi: 10.1016/j.cell.2020.06.035

    Figure Lengend Snippet: Pilot Scale Production of RBD-SC-Dimers of MERS-CoV and SARS-CoV-2 (A) RBD-sc-dimers were produced in industry-standard CHO cell system in GMP grade manufacturing. The immunogen yields and purities for vaccine stock solution are shown. (B) Non-reduced SDS-PAGE migration profile of increasing amounts of GMP grade RBD-sc-dimers are shown.

    Article Snippet: RBD-sc-dimer of SARS-CoV-2 was two RBD (S protein residues 319–537) connected as tandem repeat.

    Techniques: Produced, SDS Page, Migration

    Design and Assessment of RBD-SC-Dimer as a Vaccine against SARS-CoV-2 (A) A schematic diagram of SARS-CoV-2 RBD-sc-dimer. Two SARS-CoV-2 RBD (R319-K537) were dimerized as tandem repeat (SP, signal peptide). Analytical gel filtration of SARS-CoV-2 RBD-sc-dimer protein was performed with HiLoad 16/600 Superdex 200 pg. The 280-nm absorbance curve is shown. Non-reduced and reduced SDS-PAGE migration profiles of the pooled samples are shown. (B) Ultracentrifugation sedimentation profiles of SARS-CoV-2 RBD-sc-dimer. (C) Representative BIAcore diagrams of SARS-CoV-2 RBD-sc-dimer and monomer bound to hACE2 protein. The K D value was calculated by the software BIAevaluation Version 4.1 (GE Healthcare). The values shown are mean ± SD of two independent experiments. (D and E) Groups of BALB/c mice were immunized with a 10-μg dose of SARS-CoV-2 RBD-sc-dimer and conventional RBD-monomer, respectively, with AddaVax as adjuvant. PBS formulated with adjuvant was given as control. A three-dose vaccination regimen was performed. Serum samples were collected after each immunization (19 days after 1 st immunization, 14 days after 2 nd immunization, and 14 days after 3 rd immunization) to evaluate the humoral response dynamics. ELISA assay shows the SARS-CoV-2 RBD specific IgG titers in (D) and SARS-CoV-2 pseudovirus neutralization assay shows the NT 90 in (E). The values shown in (D) and (E) are the mean ± SEM. The horizontal dashed line indicates the limit of detection. P-values were analyzed with one-way ANOVA (ns, p > 0.05; ∗ p

    Journal: Cell

    Article Title: A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

    doi: 10.1016/j.cell.2020.06.035

    Figure Lengend Snippet: Design and Assessment of RBD-SC-Dimer as a Vaccine against SARS-CoV-2 (A) A schematic diagram of SARS-CoV-2 RBD-sc-dimer. Two SARS-CoV-2 RBD (R319-K537) were dimerized as tandem repeat (SP, signal peptide). Analytical gel filtration of SARS-CoV-2 RBD-sc-dimer protein was performed with HiLoad 16/600 Superdex 200 pg. The 280-nm absorbance curve is shown. Non-reduced and reduced SDS-PAGE migration profiles of the pooled samples are shown. (B) Ultracentrifugation sedimentation profiles of SARS-CoV-2 RBD-sc-dimer. (C) Representative BIAcore diagrams of SARS-CoV-2 RBD-sc-dimer and monomer bound to hACE2 protein. The K D value was calculated by the software BIAevaluation Version 4.1 (GE Healthcare). The values shown are mean ± SD of two independent experiments. (D and E) Groups of BALB/c mice were immunized with a 10-μg dose of SARS-CoV-2 RBD-sc-dimer and conventional RBD-monomer, respectively, with AddaVax as adjuvant. PBS formulated with adjuvant was given as control. A three-dose vaccination regimen was performed. Serum samples were collected after each immunization (19 days after 1 st immunization, 14 days after 2 nd immunization, and 14 days after 3 rd immunization) to evaluate the humoral response dynamics. ELISA assay shows the SARS-CoV-2 RBD specific IgG titers in (D) and SARS-CoV-2 pseudovirus neutralization assay shows the NT 90 in (E). The values shown in (D) and (E) are the mean ± SEM. The horizontal dashed line indicates the limit of detection. P-values were analyzed with one-way ANOVA (ns, p > 0.05; ∗ p

    Article Snippet: RBD-sc-dimer of SARS-CoV-2 was two RBD (S protein residues 319–537) connected as tandem repeat.

    Techniques: Filtration, SDS Page, Migration, Sedimentation, Software, Mouse Assay, Enzyme-linked Immunosorbent Assay, Neutralization

    Characterization of the Cellular Immune Response for COVID-19 Vaccine, Related to Figure 3 Fourty-five after the last vaccination, the splenocytes were isolated from mice vaccinated with SARS-CoV-2 RBD-sc-dimer (plus AddaVax TM adjuvant) and PBS (plus AddaVax TM adjuvant), respectively. (A) ELISPOT assay was performed to evaluate the ability of splenocytes to secrete IFN-γ following stimulation with different concentrations of peptide pool of SARS-CoV-2 RBD (2 μg/mL, 10 μg/mL and 50 μg/mL). Spot-forming cells (SFCs) per million cells are shown. (B) An ICS assay was conducted to quantify the proportion of CD8+ and CD4+ T cells producing key cytokines (IFN-γ, IL-2, TNF-α and IL-4) following stimulation with 10 μg/mL peptide pool (SARS-CoV-2 RBD). Shown are the frequencies of respective cytokine-producing cells. The values are the mean ± SEM. P-values were analyzed with unpaired t test (ns, p > 0.05).

    Journal: Cell

    Article Title: A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

    doi: 10.1016/j.cell.2020.06.035

    Figure Lengend Snippet: Characterization of the Cellular Immune Response for COVID-19 Vaccine, Related to Figure 3 Fourty-five after the last vaccination, the splenocytes were isolated from mice vaccinated with SARS-CoV-2 RBD-sc-dimer (plus AddaVax TM adjuvant) and PBS (plus AddaVax TM adjuvant), respectively. (A) ELISPOT assay was performed to evaluate the ability of splenocytes to secrete IFN-γ following stimulation with different concentrations of peptide pool of SARS-CoV-2 RBD (2 μg/mL, 10 μg/mL and 50 μg/mL). Spot-forming cells (SFCs) per million cells are shown. (B) An ICS assay was conducted to quantify the proportion of CD8+ and CD4+ T cells producing key cytokines (IFN-γ, IL-2, TNF-α and IL-4) following stimulation with 10 μg/mL peptide pool (SARS-CoV-2 RBD). Shown are the frequencies of respective cytokine-producing cells. The values are the mean ± SEM. P-values were analyzed with unpaired t test (ns, p > 0.05).

    Article Snippet: RBD-sc-dimer of SARS-CoV-2 was two RBD (S protein residues 319–537) connected as tandem repeat.

    Techniques: Isolation, Mouse Assay, Enzyme-linked Immunospot